Cannabis Bioscience International Holdings (CBIH) Common Equity (2022 - 2026)

Cannabis Bioscience International Holdings has disclosed Common Equity across 5 years of filings, most recently posting -$1.5 million for Q1 2026.

• Common Equity for Q1 2026 came in at -$1.5 million, down 19.71% year-over-year; the trailing twelve-month figure through Feb 2026 was -$1.5 million (down 19.71% YoY), and the FY2025 annual result was -$1.2 million, down 7.84% from the prior year.
• Common Equity came in at -$1.5 million for Q1 2026 at Cannabis Bioscience International Holdings, down from -$1.4 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of -$405301.0 in Q4 2022 to a low of -$1.5 million in Q1 2026.
• The 5-year median for Common Equity is -$1.1 million (2024), against an average of -$982067.9.
• Across the five-year window, Common Equity slumped 107.72% in 2023 and decreased 7.84% in 2025, its largest moves.
• Cannabis Bioscience International Holdings' Common Equity stood at -$405301.0 in 2022, then plunged by 107.72% to -$841886.0 in 2023, then tumbled by 34.8% to -$1.1 million in 2024, then dropped by 20.12% to -$1.4 million in 2025, then dropped by 7.62% to -$1.5 million in 2026.
• The last three Common Equity figures came in at -$1.5 million (Q1 2026), -$1.4 million (Q4 2025), and -$1.2 million (Q3 2025), per Business Quant data.